The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia-Pacific Region: A Cross-Sectional Real-World Study

Herr K 1 , Berk M 2 , Huang WL 3 , Kato T 4 , Lee JG 5 , Ng CG 6 Show all authors , Wang Z 7 , Webb T 1 , Kasahara-Kiritani M 8 , Vandervoort L 9

Affiliations 

  • 1 Janssen Asia Pacific, Singapore, Singapore
  • 2 School of Medicine, Deakin University, Melbourne, Australia
  • 3 Department of Psychiatry, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
  • 4 Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan
  • 5 Department of Psychiatry, College of Medicine, Haeundae Paik, Inje University, Busan, Republic of Korea
  • 6 Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 8 Janssen Pharmaceutical K.K., Tokyo, Japan
  • 9 Oracle Life Sciences, Singapore, Singapore
Neuropsychopharmacol Rep, 2025 Mar;45(1):e70007.
PMID: 40011065 DOI: 10.1002/npr2.70007

Abstract

AIM: Anhedonia is a key symptom of major depressive disorder (MDD), however, its burden in patients with MDD is not well understood. We aimed to assess the impact of anhedonia on health-related quality of life (HRQoL), health-care resource utilization (HRU), and work productivity in subjects with MDD and anhedonia (MDD-ANH) compared to subjects with MDD without ANH (MDD non-ANH).

METHODS: A cross-sectional web-based survey was conducted across six countries/territories. Adult participants were categorized as MDD-ANH, MDD non-ANH, and General Population based on self-reported MDD diagnosis, Patient Health Questionnaire (PHQ-9), and Snaith-Hamilton Pleasure Scale (SHAPS). Multivariate/generalized linear regression modeling (GLMs) and mediation analysis were used to assess anhedonia's impact on HRQoL/function, HRU, and work productivity.

RESULTS: Among 11 383 respondents, 20.1% were identified with MDD (MDD-ANH: 12.7%; MDD non-ANH: 7.3%) and 79.9% as General Population. Subjects with MDD-ANH, compared with MDD non-ANH demonstrated significantly worse or lower sexual functioning, HRQoL (RAND mental/physical component summary, health state utility (EuroQol) Index scores, all p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications